However, 10 companies defied a broader market optimism, mostly due to a series of stock rating downgrades from investment ...

On Monday, for the second time in as many business days, Illumina (NASDAQ: ILMN) stock took it on the chin because of an ...

What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) fell 7.5% in the morning session after Barclays downgraded ...

Illumina (NASDAQ:ILMN) has been cut to underweight from equal weight by Barclays over concerns the company may be facing sanctions in China and risks to its 2025 and long-range guidance. "Given our ...

Illumina (NASDAQ:ILMN – Free Report) had its price objective cut by Canaccord Genuity Group from $145.00 to $135.00 in a report published on Friday,Benzinga reports. They currently have a hold rating ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

Barclays downgraded Illumina Inc (NASDAQ:ILMN) to "Underweight" given growing uncertainty in China, rising competition from Roche in the clinical market, and weaker-than-expected elasticity in ...

Bruker shares fell by 2.5%, Illumina by 3.3%, Quanterix by 2.8%, Bio-Techne by 5%, 10X Genomics by 8.8%, and Qiagen by 3.5%. Analysts have noted that this move by the NIH could have a material impact ...

Morgan Stanley analyst Tejas Savant maintained a Hold rating on Illumina (ILMN – Research Report) today and set a price target of $136.00. The ...

In its earnings release, ILMN widened its net loss for the full year 2024 to $1.2 billion from the $1.16 billion registered ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

Star portfolio manager Cathie Wood’s Ark Investment Management filed its 13F holdings report for the fourth quarter on Feb. 4 ...